Related Experiment Video
Updated: May 27, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism
Gunjan Dhawan1, Angela M Floden, Colin K Combs
1Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58203, USA.
Abstract:
Alzheimer's disease (AD) has been well characterized by the presence of reactive microglia, often associated with β-amyloid (Aβ) plaque deposition. The oligomeric form of Aβ peptide (Aβ(o)) has neurotoxic effects in the presence of microglia and is suggested to potentiate proinflammatory changes in microglia in AD. Primary murine microglia cultures stimulated with Aβ(o) displayed increased protein phosphotyrosine and secreted tumor necrosis factor (TNF)-α levels which were attenuated by the Src/Abl inhibitor, dasatinib. Intracerebroventricular infusions of Aβ(o) into C57BL6/J mice stimulated increased microgliosis and protein phosphotyrosine levels that were also attenuated by dasatinib administration. The rodent findings were validated in human AD brains versus age-matched controls demonstrating reactive microglial association with Aβ(o) deposits and increased microglial protein phosphotyrosine and phospho-Src levels. These data suggest a role for Aβ(o) in microglial activation through a tyrosine kinase-dependant pathway both in rodent models and human disease. Use of a selective nonreceptor tyrosine kinase inhibitor such as dasatinib to attenuate microglial-dependent proinflammatory changes may prove to be an important step toward developing anti-inflammatory treatments for AD.
Insights
Alzheimer's disease involves reactive microglia. Targeting microglial activation via tyrosine kinases with drugs like dasatinib may offer new Alzheimer's treatments.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by reactive microglia and amyloid-beta (Aβ) plaques.
- Oligomeric Aβ (Aβ(o)) exacerbates neuroinflammation by activating microglia.
Purpose of the Study:
- To investigate the role of tyrosine kinases in Aβ(o)-induced microglial activation.
- To evaluate the therapeutic potential of the Src/Abl inhibitor dasatinib in Alzheimer's disease models.
Main Methods:
- Primary murine microglia cultures and C57BL6/J mice were treated with Aβ(o).
- Dasatinib was administered to assess its effect on microglial activation markers.
- Human Alzheimer's disease brain tissue was analyzed for microglial changes.
Main Results:
- Aβ(o) increased microglial protein phosphotyrosine and TNF-α levels.
- Dasatinib significantly attenuated these increases in both cell cultures and mouse models.
- Human AD brains showed increased microglial phosphotyrosine and phospho-Src levels associated with Aβ(o).
Conclusions:
- Aβ(o) activates microglia through a tyrosine kinase-dependent pathway.
- Dasatinib effectively reduces Aβ(o)-induced microglial inflammation.
- Targeting tyrosine kinases represents a promising strategy for AD anti-inflammatory therapy.
Related Concept Videos
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

